NDA 021131 · Pfizer
Zyvox
Linezolid · Intravenous · Oxazolidinone Antibacterial
Priority reviewLast checked: Nov 20, 2026Latest source record: Oct 21, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2000
Apr 18, 2000
Approved uses
5
Original approval plus efficacy supplements
Registered trials
179
68 Phase 3, 26 recruiting
FAERS reports
30,255
27,449 serious, 5,532 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Nov 3, 2026.
ZYVOX is an oxazolidinone-class antibacterial indicated in adults and children for the treatment of the following infections caused by susceptible Gram-positive bacteria: Nosocomial pneumonia ( 1.1 ); Community-acquired pneumonia ( 1.2 ); Complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis ( 1.3 ); Uncomplicated skin and skin structure infections ( 1.4 ); Vancomycin-resistant Enterococcus faecium infections. ( 1.5 ) Limitations of Use ( 1.6 ) : • ZYVOX is not indicated for the treatment of Gram-negative infections. • The safety and efficacy of ZYVOX formulations given for longer than 28 days have not been evaluated in controlled clinical trials. To reduce the development of drug-resistant bacteria and maintain the effectiveness of ZYVOX formulations and other antibacterial drugs, ZYVOX should be used only to treat or prevent infections that are proven or strongly suspected to be caused by bacteria. ( 1.7 ) 1.1 Nosocomial Pneumonia ZYVOX is indicated for the treatment of nosocomial pneumonia caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates) or Streptococcus pneumoniae [ see Clinical Studies (14) ]. 1.2 Community-acquired Pneumonia ZYVOX is indicated for the treatment of community-acquired pneumonia caused by Streptococcus pneumoniae , including cases with concurrent bacteremia, or Staphylococcus aureus (methicillin-susceptible isolates only) [ see Clinical Studies (14) ]. 1.3 Complicated Skin and Skin Structure Infections ZYVOX is indicated for the treatment of complicated skin and skin structure infections, including diabetic foot infections, without concomitant osteomyelitis, caused by Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Streptococcus...
Mechanism: ZYVOX is an antibacterial drug [ see Microbiology (12.4) ].
Therapeutic areas: Infectious disease and vaccines
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 12, 2005 Supplement 10 · Efficacy · priority review LetterLabel
- Jun 23, 2004 Supplement 7 · Efficacy · priority review LetterLabel
- Jul 22, 2003 Supplement 4 · Efficacy Letter
- Dec 19, 2002 Supplement 3 · Efficacy · priority review ReviewLetterLabel
- Apr 18, 2000 Original approval · Type 3 - New Dosage Form · priority review LetterLabelReview
3 products under this application
- ZYVOX · LINEZOLID 600MG/300ML (2MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- ZYVOX · LINEZOLID 200MG/100ML (2MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP
- ZYVOX · LINEZOLID 400MG/200ML (2MG/ML) **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · SOLUTION, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Linezolid" as an intervention, any sponsor and status, largest first.
- Platform Assessing Regimens and Durations In a Global Multisite Consortium for TBPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT06114628 · 2,500 participants (planned) · Start Jan 9, 2024 · Primary completion Feb 24, 2027
Drug: Ganfeborole; BTZ-043 and 11 more · For: Pulmonary Tuberculosis
Sites: Chisinau, Moldova; Cape Town, South Africa; George, South Africa · 11 sites in all
- Nosocomial Pneumonia With Suspected Or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00084266 · 1,225 participants · Start Oct 2004 · Primary completion Mar 2010
Drug: linezolid (Zyvox); vancomycin · For: Methicillin Resistant Staphylococcus Aureus (MRSA)
Sites: Birmingham, Alabama; Huntsville, Alabama; Montgomery, Alabama · 177 sites in all
- Linezolid or Vancomycin Surgical Site Infection ProphylaxisPivotal-lookingRecruiting
Assistance Publique Hopitaux De MarseilleAcademic, hospital or other
NCT05571722 · 1,160 participants (planned) · Start Nov 12, 2024 · Primary completion Dec 3, 2028
Drug: Vancomycin Injection; Linezolid Injection · For: Antibiotic Prophylaxis; General Surgery
Sites: Marseille, France
- Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT00087490 · 1,077 participants · Start Oct 2004 · Primary completion Jul 2007
Drug: linezolid; vancomycin · For: Skin/Soft Tissue Infections; Methicillin Resistant Staphylococcus Aureus (MRSA)
Sites: Montgomery, Alabama; Tucson, Arizona; Los Angeles, California · 126 sites in all
- Safety and Efficacy Study of Contezolid Acefosamil and Contezolid Compared to Linezolid Administered Intravenously and Orally to Adults With Moderate or Severe Diabetic Foot Infections (DFI)Pivotal-lookingRecruiting
MicuRxIndustry
NCT05369052 · 865 participants (planned) · Start May 3, 2022 · Primary completion Jun 30, 2027
Drug: contezolid acefosamil (IV)/contezolid (PO); Linezolid (IV and PO) · For: Diabetic Foot Infection
Sites: Corona, California; Vista, California; Lom, Bulgaria · 14 sites in all
- Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial PneumoniaPivotal-lookingCompleted
Melinta Therapeutics, Inc.Industry
NCT02679573 · 860 participants · Start Dec 14, 2016 · Primary completion Jul 31, 2018
Drug: Delafloxacin; Moxifloxacin and 1 more · For: Community Acquired Bacterial Pneumonia
Sites: Montgomery, Alabama; Newark, Delaware; Coral Gables, Florida · 90 sites in all
- Ceftobiprole in Hospital Acquired PneumoniaPivotal-lookingCompleted
Basilea PharmaceuticaIndustry
NCT00210964 · 781 participants · Start Apr 2005 · Primary completion May 2007
Drug: ceftobiprole plus placebo; linezolid plus ceftazidime · For: Pneumonia
- Intensified Tuberculosis Treatment to Reduce the Mortality of Patients With Tuberculous MeningitisPivotal-lookingRecruiting
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT04145258 · 768 participants (planned) · Start Feb 7, 2021 · Primary completion Sep 23, 2026
Drug: Aspirin; Placebo of aspirin and 2 more · For: Tuberculous Meningitis
Sites: Abidjan, Côte d’Ivoire; Antananarivo, Madagascar; Fianarantsoa, Madagascar · 13 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- off label use2,626
- thrombocytopenia2,242
- drug ineffective2,126
- anaemia1,777
- drug interaction1,460
- nausea1,450
- vomiting1,158
- platelet count decreased1,088
- diarrhoea1,084
- lactic acidosis1,040
- pyrexia1,039
- neuropathy peripheral1,019
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 326 |
| 2005 | 305 |
| 2006 | 546 |
| 2007 | 525 |
| 2008 | 439 |
| 2009 | 451 |
| 2010 | 897 |
| 2011 | 780 |
| 2012 | 690 |
| 2013 | 625 |
| 2014 | 563 |
| 2015 | 587 |
| 2016 | 951 |
| 2017 | 1,167 |
| 2018 | 2,670 |
| 2019 | 2,298 |
| 2020 | 2,380 |
| 2021 | 1,976 |
| 2022 | 2,407 |
| 2023 | 2,351 |
| 2024 | 2,577 |
| 2025 | 2,554 |
| 2026 | 2,190 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Zyvox (Linezolid)
2024 spending
$41K
Beneficiaries
22
23 claims
Per beneficiary
$1,871
$74.67 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $358,179 |
| 2021 | $69,591 |
| 2022 | $96,107 |
| 2023 | $50,086 |
| 2024 | $41,157 |
Part D: Zyvox (Linezolid In Dextrose 5%)
2024 spending
$33K
Beneficiaries
60
110 claims
Per beneficiary
$542
$0.12 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $74,186 |
| 2021 | $48,776 |
| 2022 | $31,067 |
| 2023 | $29,011 |
| 2024 | $32,523 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- How do I manage nocardiosis?
Margalit I, Lebeaux D, Tishler O, et al. · Clin Microbiol Infect 2021 · Systematic Review
- Linezolid-associated serotonin toxicity: a systematic review.
Elbarbry F, Moshirian N · Eur J Clin Pharmacol 2023 · Systematic Review
- Oral Regimens for Rifampin-Resistant, Fluoroquinolone-Susceptible Tuberculosis.
Guglielmetti L, Khan U, Velásquez GE, et al. · N Engl J Med 2025 · Clinical Trial, Phase III, Comparative Study
- Treatment of Highly Drug-Resistant Pulmonary Tuberculosis.
Conradie F, Diacon AH, Ngubane N, et al. · N Engl J Med 2020 · Clinical Trial, Research Support, Non-U.S. Gov't
- Bedaquiline-Pretomanid-Linezolid Regimens for Drug-Resistant Tuberculosis.
Conradie F, Bagdasaryan TR, Borisov S, et al. · N Engl J Med 2022 · Randomized Controlled Trial
- Linezolid pharmacokinetics: a systematic review for the best clinical practice.
Heidari S, Khalili H · Eur J Clin Pharmacol 2023 · Systematic Review
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.